US-based SpringWorks Therapeutics, which specialises on developing medicines and treatments for cancers and severe rare diseases, has raised $125m in a series B funding round led by Perceptive Advisors.
BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and on